This site is intended for healthcare professionals

New Spinraza data reinforce sustained efficacy and longer term safety across a broad range of Spinal Muscular Atrophy patients . Biogen Inc.

Read time: 1 mins
Last updated:20th May 2020
Published:19th May 2020
Condition: Spinal Muscular Atrophy
Type: drug
Register for free exclusive healthcare eLearning resources

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest